Loading
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Previous close
$11.42
−$0.42 · -3.55%
Regular session · ET · Market data may be delayed.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Day range
Current $11.42
52-week range
Current $11.42
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
33
Expensive
Sentiment
50
Mixed
Risk
50
Elevated Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Day range
Current $11.42
52-week range
Current $11.42
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 81.98M USD | 80.05M USD | 83.22M USD | 71.26M USD | 61.12M USD |
| Selling, general, and administrative | 21.25M USD | 18.01M USD | 16.01M USD | 15.26M USD | 13.3M USD |
| Operating expenses | 103.23M USD | 98.05M USD | 99.22M USD | 119.49M USD | 91.67M USD |
| Interest income | 1.04M USD | 3.39M USD | 3.08M USD | 1.04M USD | 66K USD |
| Interest expense | — | — | — | 1.04M USD | — |
| Depreciation and amortization | 168K USD | 134K USD | 111K USD | 77K USD | 85K USD |
| Operating income | −103.23M USD | −98.05M USD | −99.22M USD | −119.49M USD | −91.67M USD |
| Net income | −97.17M USD | −100.51M USD | −93.61M USD | −120.41M USD | −92.95M USD |
Company facts updated Sep 12, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$22.13
93.78% upsidePrice history unavailable
High $45.00Average $22.13Low $2.50| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 27, 2026 | 1:10 | — | — |
Stock split | Apr 15, 2019 | 1:40 | — | — |
Effective Apr 27, 2026
1:10
Effective Apr 15, 2019
1:40
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
